Enorama Pharma AB (SE:ERMA)
:ERMA
Want to see SE:ERMA full AI Analyst Report?
ERMA Stock Chart & Stats
kr1.91
-kr0.30(-12.50%)
At close: 4:00 PM EST
kr1.91
-kr0.30(-12.50%)
Day’s Range― - ―
52-Week Rangekr0.21 - kr3.58
Previous CloseN/A
Volume29.79K
Average Volume (3M)4.35K
Market Cap
kr24.47M
Enterprise Valuekr8.12M
Total Cash (Recent Filing)kr17.76M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.91
Shares Outstanding74,588,684
10 Day Avg. Volume2,975
30 Day Avg. Volume4,348
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)-5.66
Price to Sales (P/S)48.45
P/FCF Ratio-2.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Asset-light Licensing Business ModelAn asset-light strategy focused on partnering and licensing reduces fixed-cost burdens and capital needs, enabling Enorama to scale products through larger commercial partners. This model supports recurring milestone/royalty streams and preserves cash versus building a sales organization.
Low Financial LeverageMinimal debt lowers bankruptcy risk and interest-service pressure, providing strategic flexibility to pursue partnerships or raise growth capital. Low leverage supports survivability during extended development cycles typical for specialty pharma firms.
Proprietary, Patented FormulationsOwning patents and proprietary formulations creates durable barriers to entry, strengthens negotiating leverage with partners, and enables royalty-based monetization. IP-backed assets can translate into long-term licensing revenues if development and regulatory milestones are achieved.
Bears Say
Negative Shareholders' EquityPersistently negative equity reflects accumulated losses and weak capital base, limiting financial flexibility and potentially constraining access to non-dilutive financing. It increases reliance on external funding and raises long-term solvency and counterparty concerns.
Persistent Cash BurnSustained negative operating and free cash flow require ongoing capital injections or partner-funded programs to sustain R&D and development timelines. Continuous cash burn elevates dilution risk and can delay or derail commercialization if funding gaps occur.
Very Small, Declining Revenue And Deep LossesA shrinking, low revenue base limits operating leverage and the firm's ability to absorb R&D and commercialization costs. Combined with materially negative margins, this hampers reinvestment capacity and lengthens the path to self-sustaining profitability absent substantial partner cash or successful launches.
ERMA FAQ
What was Enorama Pharma AB’s price range in the past 12 months?
Enorama Pharma AB lowest stock price was kr0.21 and its highest was kr3.58 in the past 12 months.
What is Enorama Pharma AB’s market cap?
Enorama Pharma AB’s market cap is kr24.47M.
When is Enorama Pharma AB’s upcoming earnings report date?
Enorama Pharma AB’s upcoming earnings report date is Aug 19, 2026 which is in 62 days.
How were Enorama Pharma AB’s earnings last quarter?
Enorama Pharma AB released its earnings results on May 20, 2026. The company reported -kr0.17 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.17.
Is Enorama Pharma AB overvalued?
According to Wall Street analysts Enorama Pharma AB’s price is currently Overvalued.
Does Enorama Pharma AB pay dividends?
Enorama Pharma AB does not currently pay dividends.
What is Enorama Pharma AB’s EPS estimate?
Enorama Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enorama Pharma AB have?
Enorama Pharma AB has 74,588,684 shares outstanding.
What happened to Enorama Pharma AB’s price movement after its last earnings report?
Enorama Pharma AB reported an EPS of -kr0.17 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 23.333%.
Which hedge fund is a major shareholder of Enorama Pharma AB?
Currently, no hedge funds are holding shares in SE:ERMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Enorama Pharma AB
Enorama Pharma AB (publ) is a Swedish pharmaceutical enterprise primarily engaged in the creation, production, and distribution of specialized chewing gums. These products are formulated with established generic active ingredients. The company's offerings encompass nicotine chewing gum, designed to aid individuals in quitting smoking, as well as medical cannabis chewing gums. The cannabis-based gums are intended for a variety of applications, including non-pharmaceutical uses, along with therapeutic purposes such as targeted drug delivery through the oral lining and the treatment of allergic rhinitis. This firm operates out of its headquarters in Malmö, Sweden.